Ryan AJ - Search Results

1

Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.

Kleespies A, Köhl G, Friedrich M, Ryan AJ, Barge A, Jauch KW, Bruns CJ. Kleespies A, et al. Among authors: ryan aj. Neoplasia. 2005 Oct;7(10):957-66. doi: 10.1593/neo.05304. Neoplasia. 2005. PMID: 16242078 Free PMC article.

2

Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.

Conrad C, Ischenko I, Köhl G, Wiegand U, Guba M, Yezhelyev M, Ryan AJ, Barge A, Geissler EK, Wedge SR, Jauch KW, Bruns CJ. Conrad C, et al. Among authors: ryan aj. Anticancer Drugs. 2007 Jun;18(5):569-79. doi: 10.1097/CAD.0b013e3280147d13. Anticancer Drugs. 2007. PMID: 17414626

3

Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.

Yezhelyev MV, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A, Barge A, Green T, Fennell M, Bruns CJ. Yezhelyev MV, et al. Clin Cancer Res. 2004 Dec 1;10(23):8028-36. doi: 10.1158/1078-0432.CCR-04-0621. Clin Cancer Res. 2004. PMID: 15585638

4

Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model.

McIntyre DJ, Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Blakey DC, Peers IS, Waterton JC. McIntyre DJ, et al. Among authors: ryan aj. Neoplasia. 2004 Mar-Apr;6(2):150-7. doi: 10.1593/neo.03247. Neoplasia. 2004. PMID: 15140404 Free PMC article.

5

The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy.

Madhu B, Waterton JC, Griffiths JR, Ryan AJ, Robinson SP. Madhu B, et al. Among authors: ryan aj. Neoplasia. 2006 Jul;8(7):560-7. doi: 10.1593/neo.06319. Neoplasia. 2006. PMID: 16867218 Free PMC article.

6

Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.

Bradley DP, Tessier JJ, Ashton SE, Waterton JC, Wilson Z, Worthington PL, Ryan AJ. Bradley DP, et al. Among authors: ryan aj. Neoplasia. 2007 May;9(5):382-91. doi: 10.1593/neo.07145. Neoplasia. 2007. PMID: 17534443 Free PMC article.

7

Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

Robinson SP, Kalber TL, Howe FA, McIntyre DJ, Griffiths JR, Blakey DC, Whittaker L, Ryan AJ, Waterton JC. Robinson SP, et al. Among authors: ryan aj. Neoplasia. 2005 May;7(5):466-74. doi: 10.1593/neo.04622. Neoplasia. 2005. PMID: 15967099 Free PMC article.

8

The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.

Cesca M, Frapolli R, Berndt A, Scarlato V, Richter P, Kosmehl H, D'Incalci M, Ryan AJ, Giavazzi R. Cesca M, et al. Among authors: ryan aj. Neoplasia. 2009 Nov;11(11):1155-64. doi: 10.1593/neo.09866. Neoplasia. 2009. PMID: 19881951 Free PMC article.

9

Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ. Blakey DC, et al. Among authors: ryan aj. Clin Cancer Res. 2002 Jun;8(6):1974-83. Clin Cancer Res. 2002. PMID: 12060643

10

ZD6126: a novel small molecule vascular targeting agent.

Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. Blakey DC, et al. Among authors: ryan aj. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1497-502. doi: 10.1016/s0360-3016(02)03922-6. Int J Radiat Oncol Biol Phys. 2002. PMID: 12459377

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

679 results

Search Page

Filters